Skip to main content
Clinical Trials/NCT05086016
NCT05086016
Active, Not Recruiting
N/A

GROWTH: A Multicenter Pivotal Study of Neonatal, Infant, and Young Child Vascular Stenoses Studying the Renata Minima Stent

Renata Medical7 sites in 1 country42 target enrollmentJanuary 14, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coarctation of the Aorta
Sponsor
Renata Medical
Enrollment
42
Locations
7
Primary Endpoint
Number of Participants Demonstrating Clinical Success at 6 Months
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

The objective of the clinical investigation is to access clinical safety and effectiveness of the Minima Stent in neonates, infants, and young children requiring intervention for common congenital vascular stenosis (i.e., coarctation of the aorta and/or pulmonary artery stenosis) who are indicated for treatment.

Registry
clinicaltrials.gov
Start Date
January 14, 2021
End Date
March 30, 2028
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Renata Medical
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of Participants Demonstrating Clinical Success at 6 Months

Time Frame: Through 6-month follow-up Visit

The primary efficacy endpoint will be assessed as the rate of clinical success, with the performance goal defined as a clinical success rate of greater than 77%. Clinical success is defined as: * Stenosis relief, defined by stent outer diameter ≥ 75% of the surrounding vessel immediately after deployment. * Freedom from open surgical intervention required to treat Minima Stent disfunction through 6 months. * Maintenance of stented vessel diameter ≥ 50% of post-implant diameter at 6 months; as measured using CT angiography and/or angiography.

Number of Participants With Freedom From Serious Adverse Events at 6 Months

Time Frame: Through 6-month follow-up Visit

The primary safety endpoint will be assessed as the percentage of cases with freedom from procedure- or device-related SAEs resulting in an event listed below, with the performance goal defined as greater than 78% of cases: * Death * Cardiac arrest and/or emergency ECMO cannulation * Stroke * Limb loss * Vessel dissection of target lesion * Device thrombosis/occlusion * Cardiac perforation requiring percutaneous or open surgical intervention * Persistent cardiac arrhythmia requiring a pacemaker

Secondary Outcomes

  • Number of Patients With Arterial to Arterial Peak-to-peak Pressure Gradient of < 20 mmHg(immediately after deployment)
  • Successful Stent Re-dilation at Re-catheterization(Immediately after re-dilation)
  • Number of Patients With Freedom From Stent Embolization or Migration at 6 Months(6 months)
  • Number of Patients With Freedom From Stent Fracture at 6 Months(6 months)
  • Number of Patients With Freedom From Non-elective Minima Stent Explant at 90-days Post Re-dilation(90 days post re-dilation)
  • Number of Patients With Freedom From Procedure- or Device-related SAE During Re-dilation(Immediately after re-dilation)

Study Sites (7)

Loading locations...

Similar Trials